Business Daily from THE HINDU group of publications
Friday, Oct 26, 2007
ePaper | Mobile/PDA Version
Business Daily from THE HINDU group of publications Friday, Oct 26, 2007 ePaper | Mobile/PDA Version |
|
|
|
|
|
|
|
|
|
|
|
Home Page
-
Financial Performance Corporate Results - Pharmaceuticals Money & Banking - Forex
Our Bureau Mumbai, Oct. 25 Drug-maker Cipla expects the strong rupee to impact both sales and profits in the current quarter, its Chief Executive Officer Mr Amar Lulla said. The company’s performance for the three months under review, ended September 30, 2007, was buoyed by a 20 per cent growth in its topline, said the official. And if it were not for the strong rupee, Cipla would have seen better export figures, he indicated. Cipla’s domestic sales grew by about 15 per cent and the export segment grew by about 25 per cent for the quarter under review. Formulation exports grew by 45 per cent, while it could have grown over 60 per cent, if not for the strong rupee, he said. The export of active pharmaceutical ingredients saw a 11 per cent dip. Exports account for about 52 per cent of total sales. Domestic performanceAll the major segments including anti-asthmatics, cardiovascular, anti-biotics/bacterials and anti-retrovirals segments have shown satisfactory performance in the domestic market, a Cipla statement said. In the exports market, anti-retrovirals, anti-asthmatics and anti-malarials performed well, the company added. Though material cost and other expenditure were in line with the previous quarter, operating margins were higher due to technical fees received during the quarter, the company said. Other expenditure had gone up by more than Rs 60 crore, largely due to increased expenditure on advertisement campaign, travel expenditure and sales expenditure, it added. Cipla plans Rs 950-cr capacity expansion Cipla Q1 net profit down 30% Cipla Q2 net profit up 47 pc Clinton Foundation, Cipla pact to supply anti-AIDS drugs for children More Stories on : Financial Performance | Pharmaceuticals | Forex | Cipla Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2007, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|
